#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glioma Immune-mediated myasthenia gravis Pseudomyxoma peritonei B-cell lymphoma recurrent Sjogren's syndrome Amyotrophic lateral sclerosis gene carrier Phaeochromocytoma Oesophageal achalasia Lennox-Gastaut syndrome Necrotising myositis Marfan's syndrome Keratosis follicular Rhabdomyosarcoma Small cell lung cancer Mixed-type liposarcoma More trials…

    Learn about Rare Diseases

    Pulmonary sarcoidosis – Basic Information Waldenstrom’s macroglobulinaemia Wolfram syndrome – Trials in Disease Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Medulloblastoma recurrent – Trials in Disease Gastrointestinal stromal tumour – Life with Disease Factor VIII deficiency – Life with Disease Myxofibrosarcoma – Basic Information Aicardi-Goutieres syndrome – Basic Information Haemophagocytic lymphohistiocytosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tusamitamab Ravtansine Ulonivirine Benztropine Mesylate Cedazuridine Oxycodone Hydrochloride Petrelintide Dexamethasone Acetate Cx-037231 Pimozide TIL CELLS Incb099280 L-Glutamic Acid Acasunlimab Ciprofloxacin Oxymetazoline Hydrochloride Nirogacestat Hydrobromide Doxycycline Hyclate Blomia Tropicalis Glatiramer Acetate Docetaxel More therapies…

    Learn about Your Condition

    Lymphocytic lymphoma Hypertension Familial mediterranean fever Muscular dystrophy Dent's disease Vestibular disorder Large cell lung cancer stage 0 Premature baby Endotracheal intubation Craniotomy Respiratory failure Laryngeal cancer Complex regional pain syndrome Habitual abortion Elderly More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Capio La Croix Du Sud

Capio La Croix Du Sud

52 Chemin De Ribaute, Quint-Fonsegrives, 31130, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium Czechia France Germany Italy The Netherlands +3

  • Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium France Germany Italy The Netherlands Spain

  • Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Mitomycin
    • Gemcitabine Hydrochloride
    Belgium France Germany Italy Poland Romania +1

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Palbociclib
    France

  • Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    • Enfortumab Vedotin
    Austria France Germany Greece Italy The Netherlands +3

  • Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Other Hormone Antagonists And Related Agents
    • Tumour Detection
    • Apalutamide
    Czechia France Germany Italy The Netherlands Poland +1

  • Study on Surgery with or without Darolutamide for Patients with High-Risk or Locally Advanced Prostate Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Darolutamide
    France

  • Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colon cancer
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Irinotecan
    France Italy

  • Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Degarelix
    • Relugolix
    Czechia France Germany Italy The Netherlands Poland +1
Previous Page
1 2 3

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!